Business Context and Reporting Period
This Form 8-K Current Report was filed by MRI Interventions, Inc. on September 25, 2018. The filing discloses significant corporate actions regarding the company's debt obligations, specifically the repayment of a promissory note to Brainlab AG and the amendment of terms for its 12% Second-Priority Secured Non-Convertible Promissory Notes.
Key Financial Metrics and Debt Activity
- Debt Repayment: The Company repaid approximately $2.026 million in total, covering principal, interest, and other amounts due under the Second Amended and Restated 5.5% Promissory Note (the "Brainlab Note").
- Debt Restructuring: The Company holds 12% Second-Priority Secured Non-Convertible Promissory Notes Due 2019 with an aggregate principal balance of approximately $2 million.
- Liquidity Impact: The filing does not provide specific cash balance figures or liquidity ratios, but the repayment of $2.026 million indicates a significant cash outflow.
Material Changes Versus Prior Period
- Termination of Agreement: The Master Security Agreement dated April 5, 2011, with Brainlab AG was terminated. All liens granted in connection with the Brainlab Note were released.
- Extension of Maturity: The maturity date of the $2 million in 12% Notes was extended by 18 months, moving the due date from 2019 to September 2020.
Management Commentary, Risks, and Unusual Items
Management executed these transactions to restructure its capital structure. The repayment of the Brainlab Note eliminated a specific debt obligation and associated liens. The extension of the 12% Notes was agreed upon with holders representing a majority of the aggregate principal balance. The filing includes a press release (Exhibit 99.1) detailing these events but does not provide forward-looking guidance, revenue projections, or specific risk factors beyond the standard disclosure language regarding the amendment summary.
Investor Verification Checklist
- Verify the source of funds used to repay the $2.026 million Brainlab Note obligation.
- Confirm the total outstanding principal and accrued interest on the 12% Notes as of the filing date.
- Review the full text of the Third Omnibus Amendment (Exhibit 10.1) for any covenants or conditions attached to the maturity extension.
- Assess the impact of the 12% interest rate on future cash flow requirements given the extended maturity.